Original Article
Split Viewer
Blood Res 2019; 54(1):
Published online March 31, 2019
https://doi.org/10.5045/br.2019.54.1.57
© The Korean Society of Hematology
ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy
1Hematology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
2Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Correspondence to : Correspondence to Ahmed M. L. Bedewy, M.D. Hematology Department, Medical Research Institute, Alexandria University, Abraj Al-Shaker from Zaky Ragab Street, Smouha, Alexandria 21615, Egypt. dr_ahmed_bedewy@yahoo.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
ATP-binding cassette transporters are important in the mechanism of multidrug resistance. ABCB1 displays a high affinity for imatinib. BMI1 is a polycomb group protein thought to be overexpressed in leukemic cells.
Methods
This study was conducted to investigate the prognostic value of ABCB1 and BMI1 expressions in chronic myeloid leukemia (CML). Expression levels were measured in 81 patients newly diagnosed with CML and 20 healthy controls by real time reverse transcription- PCR.
Results
The ABCB1 expression levels did not differ between patients with CML and controls. Low ABCB1 mRNA levels were observed in patients who achieved an optimal response compared to suboptimal and resistant cases (
Conclusion
ABCB1 mRNA expression may serve as a predictor of the optimal response to imatinib treatment in patients with CML. BMI1 expression was higher in the accelerated and blastic crisis phases of CML and associated with a shorter PFS.
Keywords ABCB1, BMI1, Chronic myeloid leukemia, Imatinib, TKI resistance, Real-time PCR
PDF
Standard view
Export citation
Share Article
Original Article
Blood Res 2019; 54(1): 57-62
Published online March 31, 2019 https://doi.org/10.5045/br.2019.54.1.57
Copyright © The Korean Society of Hematology.
ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy
Ahmed M. L. Bedewy1*, Shereen M. Elmaghraby1, and Noha S. Kandil2
1Hematology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
2Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Correspondence to:Correspondence to Ahmed M. L. Bedewy, M.D. Hematology Department, Medical Research Institute, Alexandria University, Abraj Al-Shaker from Zaky Ragab Street, Smouha, Alexandria 21615, Egypt. dr_ahmed_bedewy@yahoo.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background
ATP-binding cassette transporters are important in the mechanism of multidrug resistance. ABCB1 displays a high affinity for imatinib. BMI1 is a polycomb group protein thought to be overexpressed in leukemic cells.
Methods
This study was conducted to investigate the prognostic value of ABCB1 and BMI1 expressions in chronic myeloid leukemia (CML). Expression levels were measured in 81 patients newly diagnosed with CML and 20 healthy controls by real time reverse transcription- PCR.
Results
The ABCB1 expression levels did not differ between patients with CML and controls. Low ABCB1 mRNA levels were observed in patients who achieved an optimal response compared to suboptimal and resistant cases (
Conclusion
ABCB1 mRNA expression may serve as a predictor of the optimal response to imatinib treatment in patients with CML. BMI1 expression was higher in the accelerated and blastic crisis phases of CML and associated with a shorter PFS.
Keywords: ABCB1, BMI1, Chronic myeloid leukemia, Imatinib, TKI resistance, Real-time PCR
Fig 1.
Download
Kaplan-Meier analysis of progression hazard according to ABCB1 expression level (
Fig 2.
Download
Kaplan-Meier analysis of progression hazard according to BMI1 expression level (
-
Expression levels of ABCB1 and BMI1 in cases and controls. a)
P -value of Mann-Whitney test. *Significant..
-
ABCB1 and BMI1 expression in relation to the studied parameters. a)
P -value of student t test. b)P -value of Chi square test. c)P -value of Wilcoxon Signed Rank test. d)P -value of Monte Carlo test. *Significant..
-
Response to imatinib in relation to ABCB1 and BMI1 expression. a)
P -value of Mann-Whitney test. *Significant..
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Jae Joon Han
Blood Res 2023; 58(S1): S58-S65 -
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
Maria Gemelli, Elena Maria Elli, Chiara Elena, Alessandra Iurlo, Tamara Intermesoli, Margherita Maffioli, Ester Pungolino, Maria Cristina Carraro, Mariella D’Adda, Francesca Lunghi, Michela Anghileri, Nicola Polverelli, Marianna Rossi, Mattia Bacciocchi, Elisa Bono, Cristina Bucelli, Francesco Passamonti, Laura Antolini, Carlo Gambacorti-Passerini
Blood Res 2020; 55(3): 139-145 -
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Jieun Uhm
Blood Res 2023; 58(S1): S109-S113
